Indivumed and Biognosys partnership aims to enhance proteomics insights

Indivumed, a physician-led, integrated global oncology solution provider, announced today its partnership with Biognosys, a leader in next-generation proteomics solutions. This partnership represents the next step in enriching IndivuType multi-omics cancer database with proteome-level data from thousands of samples using Biognosys’ cutting-edge proteomics technology to enable novel discoveries in cancer biology.

Image Credit: Shutterstock/CI Photos

The promise of precision oncology demands the development of patient-specific molecular and phenotypic cancer signatures, and research has shown that evaluating genomic data alone has its limitations. IndivuType is the result of more than fifteen years’ experience in collecting and curating highquality cancer biospecimens through partnerships with leading healthcare institutions around the world. Only high-quality samples can produce reliable data enabling novel discoveries in cancer biology. IndivuType cancer database provides rich and deep information through analyzing multiple omics layers, including genomics, transcriptomics, proteomics, phosphoproteomics and immunophenotyping in combination with complete clinical and outcome data thus making it a powerful and unique resource for the cancer community worldwide.

Robust and reliable proteomics and phosphoproteomics analysis is greatly dependent on sample quality and processing techniques. The IndivuType ecosystem begins with stringent SOP-driven sample collection procedures across Indivumed’s global clinical network combined with thorough validation of clinical information and data integrity. These high-quality samples are analyzed with Biognosys’ innovative and robust solutions for highly multiplexed protein quantification, which will add a critical component to augment IndivuType multi-omics database.

Biognosys, a Swiss proteomics company, develops next-generation mass spectrometry-based proteomics technologies (HRM™) that achieve unprecedented sensitivity and depth with high reproducibility from
low microgram amounts of protein. The HRM technology enables profiling of protein expression and phosphorylation in large sample cohorts. Thousands of proteins can be quantified simultaneously in a single measurement. Since next-generation proteomics is a label-free method, it is applicable in all species across a wide range of sample types including tissue samples and body fluids for biomarker discovery and mechanism of action studies.

We are very excited with this partnership. Proteomics and phosphoproteomics play a crucial role in understanding cancer biology and adding Biognosys’ technology to the IndivuType multi-omics profile will enable relevant discoveries in our collaborations with pharma and biotech.”  

Dr. Hartmut Juhl, Indivumed CEO and founder

“The IndivuType project is at the forefront of multi-omics cancer profiling”, says Dr. Oliver Rinner, CEO and founder of Biognosys. “Indivumed’s focus on sample quality and scale is unique in the field. Proteomics has long been known as a relatively low sample throughput technology. With the development of the parallel acquisition based next-generation technology, proteomics has become both, more sensitive and higher throughput. This has been the basis for our partnership. We are convinced that large scale proteomics and phosphoproteomics data from well characterized sample cohorts will add a highly relevant new dimension to quantitative biology, and specifically to cancer biology.“

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Biognosys. (2020, October 01). Indivumed and Biognosys partnership aims to enhance proteomics insights. News-Medical. Retrieved on June 18, 2021 from https://www.news-medical.net/news/20200204/Indivumed-and-Biognosys-partnership-aims-to-enhance-proteomics-insights.aspx.

  • MLA

    Biognosys. "Indivumed and Biognosys partnership aims to enhance proteomics insights". News-Medical. 18 June 2021. <https://www.news-medical.net/news/20200204/Indivumed-and-Biognosys-partnership-aims-to-enhance-proteomics-insights.aspx>.

  • Chicago

    Biognosys. "Indivumed and Biognosys partnership aims to enhance proteomics insights". News-Medical. https://www.news-medical.net/news/20200204/Indivumed-and-Biognosys-partnership-aims-to-enhance-proteomics-insights.aspx. (accessed June 18, 2021).

  • Harvard

    Biognosys. 2020. Indivumed and Biognosys partnership aims to enhance proteomics insights. News-Medical, viewed 18 June 2021, https://www.news-medical.net/news/20200204/Indivumed-and-Biognosys-partnership-aims-to-enhance-proteomics-insights.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Biognosys brings proteomic breakthroughs to mainstream users